Company news
Onco-innovations Ltd. (NEO:ONCO) news
Onco-innovations Ltd. news releases on 6ix. Latest, Dec 7, 2025: Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential…
Press releases — page 2
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
December 7, 2025
Onco-Innovations Attends University of Alberta's 2025 Innovation Awards
November 25, 2025
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
November 20, 2025
Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
November 18, 2025
Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
November 7, 2025
Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight
October 31, 2025
Onco-Innovations Appoints Jared Rushton to Board of Directors
October 30, 2025
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
October 7, 2025
Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology
September 28, 2025
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
September 26, 2025
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 26, 2025
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
September 22, 2025
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
September 19, 2025
Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care
September 12, 2025
Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board
September 5, 2025
Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised
August 15, 2025
Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement
August 4, 2025
Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
July 20, 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)
July 17, 2025
ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders
July 16, 2025
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
July 16, 2025
Onco-Innovations Signs Agreement with Redwood AI to Advance Discovery and Evaluation of Its PNKP Inhibitor Technology
July 11, 2025
Onco-Innovations Strengthens Clinical Leadership with Appointment of Dr. Islam Mohamed as Advisory Board Chair
July 10, 2025
Onco-Innovations Enters Agreement with Nucro-Technics for IND-Enabling Studies, Taking a Key Step Toward Human Trials
July 4, 2025
Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call
July 2, 2025
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
June 27, 2025
Onco-Innovations' CEO to Host Special Investors' Conference Call on Wednesday, July 2, 2025
June 25, 2025
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
June 16, 2025
Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers
June 13, 2025
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
June 11, 2025
Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research
June 5, 2025
Onco-Innovations Announces Start of Manufacturing of Preclinical Testing Material for Its PNKP Inhibitor Technology by Dalton Pharma
May 26, 2025
Onco-Innovations Extends Marketing Program
May 26, 2025
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
May 22, 2025
Onco-Innovations Celebrates Listing of Common Shares on Cboe Canada
May 16, 2025
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
March 19, 2025